RYTM · earnings call history
Rhythm Pharmaceuticals Q2 FY26 — Strong IMCIVREE HO Launch and Promising RM-718 Data
Read the briefRhythm Pharmaceuticals Q1 FY26 — Strong HO Launch and Pipeline Progress
Read the briefRhythm Pharmaceuticals Q4 FY25 — Strong IMCIVREE Sales and Bivamelagon Phase 3 Progress
Read the briefBrowse all US companies on the earnings-call register.